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Abstract 
Triple  negative  breast  cancers  are  aggressive  breast  tumors  that  are  characterized  
by  the  absence  of  estrogen  receptor,  progesterone  receptor,  and  HER2.  This  absence  of  
expression  limits  targeted  therapeutic  strategies.  The  result  is  a  disease  that  is  associated  
with  a  poor  prognosis.  The  current  survival  rate  for  those  afflicted  with  triple  negative  
breast  cancer  is  77%.  This  survival  rate  is  compared  to  a  93%  survival  rate  for  all  other  
breast  cancers  combined.  Furthermore,  triple  negative  breast  cancers  disproportionately  
affect  young  and  African  American  women.    
The  Carolina  Breast  Cancer  Study  demonstrated  that  obesity  increased  the  risk  of  
triple  negative  breast  cancer  in  premenopausal  women.  These  findings  were  supported  
by  a  meta-­‐‑analysis  of  11  epidemiological  studies  evaluating  the  association  between  
triple  negative  breast  cancer,  obesity,  and  menopause  status.  Consequently,  it  is  
hypothesized  that  obesity  in  premenopausal  women  may  contribute  to  the  initiation  and  
progression  of  triple  negative  breast  cancer.    
On  average,  adipose  constitutes  70%  of  the  breast.  Obesity  is  a  disease  of  
increased  adipose  tissue,  which  can  increase  the  adiposity  of  the  breast.  Studies  show  
that  obesity  enhances  the  production  of  the  inflammatory  cytokines  IL1β,  IL6,  IL8,  
TNFα,  and  MCP-­‐‑1  in  adipose  tissue.  Inflammatory  cytokines  contribute  to  proliferation  
and  survival  of  malignant  cells,  migration  and  invasion,  and  induction  of  epithelial  to  
mesenchymal  transition  (EMT).    
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The  purpose  of  this  study  is  to  investigate  the  role  of  adipose  derived  cytokines  
in  promotion  of  EMT  and  invasion  in  early  mammary  carcinogenesis.  To  study  EMT  
and  invasion  in  early  mammary  carcinogenesis,  a  co-­‐‑culture  was  generated  using  
adipose  stromal  cell  (ASC)  conditioned  media  and  the  non-­‐‑transformed,  mammary  
epithelial  cell  line  MCF10A.  ASC-­‐‑conditioned  media  was  characterized  for  cytokine  
production.  Findings  indicated  that  IL6,  IL8,  and  MCP-­‐‑1  were  secreted  into  the  media.  
Researchers  have  extensively  studied  IL6  and  IL8  in  breast  EMT,  but  the  relevance  of  
MCP-­‐‑1  in  breast  carcinogenesis  has  only  recently  emerged.  MCP-­‐‑1  is  involved  in  
monocyte  and  macrophage  trafficking,  renal  fibrosis  and  EMT,  as  well  as  EMT  in  
peritoneal  disease.  The  role  of  MCP-­‐‑1  in  renal  and  peritoneal  EMT  suggests  that  MCP-­‐‑1  
may  induce  EMT  in  mammary  epithelial  cells.    
MCP-­‐‑1  did  not  alter  the  protein  expression  levels  of  either  E-­‐‑cadherin  or  
Vimentin  in  2D  culture.  MCP-­‐‑1  treatment  did,  however,  rapidly  phosphorylate  Erk1/2  at  
T202/Y204  and  induce  chemotaxis  of  MCF10A  cells  in  a  Boyden  Chamber  migration  
assay.  Erk1/2  phosphorylation  and  chemotaxis  were  inhibited  by  pretreatment  with  
PD98059,  a  potent  small  molecule  inhibitor  of  Erk  signaling.    
In  3D,  MCF10A  acini  treated  with  MCP-­‐‑1  lost  expression  of  E-­‐‑cadherin,  β-­‐‑
catenin,  and  localized  areas  of  Integrin  α6.  Additionally,  MCP-­‐‑1  induced  outgrowth  
away  from  the  MCF10A  spheroids  and  invasion  into  the  extracellular  matrix  during  a  
spheroid  gel  invasion  assay.  MCP-­‐‑1  did  not  induce  the  secretion  of  MMP-­‐‑2  or  MMP-­‐‑9  
during  invasion.  When  the  MCP-­‐‑1  treated  acini  and  spheroids  were  co-­‐‑treated  with  
PD98059  E-­‐‑cadherin  loss  and  invasion  were  inhibited  respectively.  This  inhibition  
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suggests  that  Erk  activation  is  necessary  for  E-­‐‑cadherin  loss  and  cell  invasion.  The  data  
indicate  that  MCP-­‐‑1  plays  a  potential  role  in  the  early  EMT  and  invasion  of  non-­‐‑
transformed,  mammary  epithelial  cells.  This  study  provides  a  foundation  for  the  study  
of  MCP-­‐‑1  induced  EMT  and  invasion  in  MCF10A  cells.  Further  work  will  need  to  be  
completed  to  elucidate  the  mechanism  by  which  MCP-­‐‑1  decreases  E-­‐‑cadherin  and  
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1 Introduction 
Breast  cancer  is  the  most  common  cancer  among  women  (1).    According  to  the  
National  Cancer  Institute,  based  on  current  incidence  rates,  12.4%  of  women  born  in  the  
United  States  today  will  get  breast  cancer  in  their  lifetime  (2).  Despite  current  incidence  
rates,  there  has  been  an  increase  in  breast  cancer  survival  rates  over  the  past  few  
decades.  In  1975,  the  overall  survival  rate  of  women  diagnosed  with  breast  cancer  in  the  
United  States  did  not  exceed  75%.  Currently,  however,  this  survival  rate  is  now  
approaching  90%  (3).    This  increase  in  survival  can  be  attributed  to  earlier  detection,  
improved  treatment,  and  targeted  therapies.    
Breast  cancer  is  not  a  homogenous  disease  and  is  characterized  by  the  expression  
of  its  cell  surface  receptors.  Breast  cancers  are  subtyped  by  the  expression  of  three  cell  
surface  receptors:  estrogen  receptor  (ER),  progesterone  receptor  (PR),  and  human  
epidermal  growth  factor  receptor  2  (Her2).  A  breast  cancer  that  lacks  the  expression  of  
these  three  receptors  is  a  triple-­‐‑negative  breast  cancer  (TNBC)  (4).  Triple  negative  
tumors  are  associated  with  a  poor  prognosis  because  there  are  no  established  targeted  
therapies.  The  current  survival  rate  of  women  with  TNBCs  is  77%,  compared  to  93%  for  
all  other  breast  cancer  patients  combined  (5).    
1.1 Disparities in Breast Cancer 
Triple  negative  breast  cancers  occur  more  often  in  young  and  African  American  
women  (5-­‐‑7,  85,  95-­‐‑99).  A  study  stratifying  the  age  of  women  diagnosed  with  TNBC  
showed  that  63.1%  of  female  patients  with  a  triple  negative  tumor  were  under  the  age  of  
60  (95).  The  Carolina  Beast  Cancer  Study  stratified  their  patients  by  menopausal  status  
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and  showed  that  64%  of  triple  negative  tumors  occurred  in  premenopausal  women  (7).  
In  addition  to  increased  incidences  of  TNBC,  it  was  shown  that  young  women  (31-­‐‑40  
years  old)  diagnosed  with  TNBC  had  a  shorter  disease-­‐‑free  state  and  overall  length  of  
survival  when  compared  to  older  women  (>60  years  old)  (96).    
African  American  women  are  up  to  three  times  as  likely  to  be  diagnosed  with  
triple  negative  tumors  as  Caucasian  women  (7,  97,  99-­‐‑100).  Additionally,  African  
American  women  with  TNBC  have  a  higher  mortality  rate  than  Caucasian  women  even  
after  adjusting  for  age,  stage,  and  grade  of  tumor  (97-­‐‑100).    
Within  the  population  of  African  American  women,  investigations  have  shown  
that  young  African  American  women  have  higher  TNBC  rates  than  older  African  
American  women.  The  Carolina  Breast  Cancer  Study  showed  that  TNBC  was  more  
prevalent  among  premenopausal  African  American  women  (39%)  compared  with  
postmenopausal  women  (14%).  It  was  further  shown  that  TNBC  was  less  prevalent  in  
non-­‐‑African  American  women  of  any  age  (16%)  (7).  
The  Carolina  Breast  Cancer  Study  then  examined  the  role  of  obesity  in  breast  
cancer  subtypes.  It  was  shown  that  obesity  in  premenopausal  women  was  associated  
with  increased  risk  of  TNBCs,  while  obesity  in  postmenopausal  women  was  associated  
with  increased  risk  of  ER+  breast  cancers  (9).  A  meta-­‐‑analysis  of  11  epidemiological  
studies  evaluating  the  association  between  TNBC,  obesity,  and  menopause  status  
further  supported  the  findings  that  obesity  was  associated  with  increased  risk  of  TNBC  
in  premenopausal  women  (101).  Consequently,  obesity  in  premenopausal  women  may  
contribute  to  the  formation  of  TNBC.  
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1.2 Signaling Pathways in TNBC 
To  better  understand  the  molecular  pathways  involved  in  TNBC  and  identify  
molecular  based  therapies,  a  meta-­‐‑analysis  of  587  triple  negative  breast  tumor  gene  
expression  arrays  was  performed.  The  investigators  identified  six  distinct  molecular  
subtypes  of  TNBC  (11).    Two  of  these  subtypes  occur  at  a  higher  frequency  in  African  
American  women  and  have  a  worse  prognosis:  the  Mesenchymal-­‐‑like  and  Mesenchymal  
Stem-­‐‑like.  Both  subtypes  were  so  named  because  they  were  enriched  for  epithelial-­‐‑
mesenchymal  transition  (EMT)  markers  and  growth  factor  pathways.  Upon  closer  
observation  of  the  gene  set  enrichment  analysis,  it  is  apparent  that  the  Mesenchymal  
Stem-­‐‑like  subtype  has  increased  expression  of  transcripts  from  genes  sets  for  both  
adipocytokine  signaling  pathways  (KEGG_Adipocytokine_signaling_pathway  -­‐‑  69  
genes)  and  ERK1/2  signaling  pathways  (Biocarta_ERK_pathway  –  28  genes)  (11).  
Activation  of  adipocytokine  pathways  suggests  increased  adipose  signaling,  which  is  
associated  with  obesity  (13-­‐‑15).  
Increased  Erk1/2  signaling  is  associated  with  more  aggressive  TNBC  cases  with  
poorer  outcomes.  Triple  negative  breast  tumors  were  measured  by  reverse  phase  protein  
microarray  and  showed  increased  phosphorylation  of  Erk1/2  T202/Y204  and  
downstream  targets  (12).    
Activation  of  Erk  is  associated  with  obesity.  Obesity  increases  the  amount  of  
circulating  cytokines  produced  by  adipose  tissue  (13,  15).  Several  of  these  cytokines;  IL6,  
IL8,  Leptin,  and  MCP-­‐‑1;  have  been  shown  to  phosphorylate  Erk1/2  at  T202/Y204  (57-­‐‑58,  
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80-­‐‑82).  The  increase  of  circulating  cytokines  that  result  in  Erk1/2  phosphorylation  
suggests  that  obesity  correlates  with  increased  Erk  signaling  in  tissues.    
Previously  published  work  suggests  a  link  between  high-­‐‑risk  TNBC,  EMT,  and  
obesity  in  early  mammary  carcinogenesis  (16).  Cytological  samples  were  acquired  from  
a  cohort  of  women  who  were  high  risk  for  breast  cancer  and  analyzed  using  reverse-­‐‑
phase  protein  microarray.  Women  were  considered  high  risk  if  they  had  one  of  the  
following  major  risk  factors:  a  5-­‐‑year  Gail  risk  calculation  of  greater  than  1.7%;  a  prior  
biopsy  exhibiting  atypical  hyperplasia,  lobular  carcinoma  in  situ,  or  ductal  carcinoma  in  
situ;  or  known  BRCA1/2  mutation  carrier.  It  was  observed  that  the  mesenchymal  marker  
Vimentin  correlated  with  obesity  (16).      
Within  the  same  study,  it  was  shown  that  many  of  the  samples  had  an  increase  in  
Erk1/2  phosphorylation  (16).  Furthermore,  a  separate  study  showed  that  constitutively  
activated  Erk  signaling  induced  EMT  (61).  
Taken  together,  Erk  signaling  is  activated  in  aggressive  TNBC  and  in  early  
precancerous  cytological  samples  from  a  cohort  of  women  who  are  high-­‐‑risk  for  breast  
cancer.  Additionally,  the  mesenchymal  marker  Vimentin  correlated  with  obesity  in  the  
same  cohort  of  women.  Lastly,  Erk  signaling  is  associated  with  obesity  and  has  been  
shown  to  induce  EMT.    
1.3 Epithelial-Mesenchymal Transition 
Epithelial-­‐‑mesenchymal  transition  is  defined  as  a  biologic  process  that  allows  a  
polarized  epithelial  cell,  which  normally  interacts  with  a  basement  membrane  via  its  
basal  surface,  to  undergo  multiple  biochemical  changes  that  enable  it  to  assume  a  
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mesenchymal  cell  phenotype  (20).  EMT  enhances  migratory  capacity,  invasiveness,  
elevated  resistance  to  apoptosis,  and  greatly  increased  production  of  extracellular  matrix  
(ECM)  components  (20).    Typical  of  many  cancerous  processes,  the  transition  from  an  
epithelial  state  to  a  mesenchymal  state  occurs  normally  during  development,  but  is  
hijacked  by  transformed  cells  (22).  EMT  is  measured  by  the  loss  of  epithelial  markers  
such  as  E-­‐‑cadherin,  Cytokeratin,  and  ZO-­‐‑1,  and  by  the  acquisition  of  mesenchymal  
markers  such  as  Vimentin,  N-­‐‑cadherin,  and  Fribronectin.  EMT  is  controlled  by  a  set  of  
master  EMT  regulating  transcription  factors  including  but  not  limited  to:  Twist1/2,  
Zeb1/2,  Snail  and  Slug  (20-­‐‑23).  Furthermore,  EMT  is  commonly  associated  with  TNBC  
(11,  24)  and  several  triple  negative  cell  lines  have  been  shown  to  express  multiple  EMT  
markers  (25).    
Both  cytokines  and  growth  factors  have  been  shown  to  induce  EMT  in  a  number  
of  transformed  and  non-­‐‑transformed  cell  lines  (26-­‐‑29).    The  cytokines  TGF-­‐‑β,  TNFα,  IL6,  
IL8,  and  Leptin  have  all  demonstrated  induction  of  EMT  in  vitro  (26-­‐‑30,  32-­‐‑33,  89).  Most  
of  these  cytokines  are  also  secreted  by  adipose  tissue,  which  makes  up  an  average  of  
70%  of  the  breast  microenvironment  (13,  34).    
1.4 Breast Microenvironment 
The  breast  terminal  ductal  lobular  unit  is  composed  of  a  layer  of  luminal  
epithelial  cells  surrounded  by  myoepithelial  cells,  which  are  attached  to  a  basement  
membrane.  Encompassing  the  terminal  ductal  lobular  unit  are  stromal  cells,  which  
include  endothelial  and  immune  cells,  fibroblasts  and  adipocytes.  Extracellular  matrix  
proteins  secreted  by  stromal  cells  support  the  branching  duct  structure.  Additionally,    
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cytokines  are  secreted  by  all  of  the  cells  surrounding  the  terminal  ductal  lobular  unit  
(35).  Subcutaneous  adipose  tissue  surrounds  the  branching  ducts  and  terminal  ductal  
lobular  units  (34-­‐‑35).  
1.4.1 Adipose Tissue 
Adipose  tissue  was  once  viewed  as  an  inert  tissue  that  provided  insulation  to  the  
body.  Now,  adipose  tissue  is  recognized  as  an  endocrine  organ  that  secretes  hormones,  
cytokines,  chemokines,  growth  factors  and  adipokines  (36).  On  average,  the  breast  is  
composed  of  70%  adipose  tissue  (34).  Obesity  increases  the  inflammatory  cytokines  
IL1β,  IL6,  IL8,  TNFα,  and  MCP-­‐‑1  in  adipose  tissue  (35-­‐‑37,  50-­‐‑51,  81,  87-­‐‑88).  Recognizing  
this,  several  groups  have  studied  the  cytokines  and  growth  factors  secreted  by  adipose  
tissue  in  in  vitro  transformed  cell  and  non-­‐‑transformed  cell  models  (37-­‐‑39).  While  not  
exhaustive,  this  list  includes:  IL6,  IL8,  IL1β,  TNFα,  VEGF,  HGF,  M-­‐‑CSF,  leptin  and  
adiponectin  (13,  39).  
1.4.1.1  Adipose  in  Cell  Culture  
Mature  adipocytes  are  terminally  differentiated,  and  thus,  will  not  grow  in  
culture.  Therefore,  in  vitro  studies  are  difficult  to  perform.  To  overcome  this  obstacle,  
researchers  have  devised  different  approaches  to  studying  adipose  cytokine  production  
on  different  cell  lines.  The  crudest  way  to  study  this  is  to  incubate  adipose  tissue  
collected  from  a  patient  directly  in  media,  and  to  collect  the  media  for  use  on  cell  lines  
(40).  This  method  uses  primary  mature  adipocytes,  but  included  in  the  adipose  tissue  
are  other  stromal  cells:  fibroblasts  and  immune  cells.  Additionally,  it  is  not  possible  to  
control  cell  numbers  when  using  primary  patient  adipose  tissue  to  condition  the  media.      
	  	   7  
In  lieu  of  mature  adipocytes,  many  groups  utilize  the  adipose  precursor,  adipose  
stromal  cells  (ASC).  The  use  of  ASCs  allows  the  propagation  of  adipose  precursors  and  
the  differentiation  of  ASCs  into  mature  adipocytes  as  needed.  Both  ASCs  and  mature  
adipocytes  can  be  used  to  condition  media  in  order  to  study  adipose-­‐‑derived  cytokines  
in  vitro.  There  are  different  ASC  models  preferred  in  in  vitro  adipose  research.  Some  
groups  utilize  the  established  murine  pre-­‐‑adipocyte  line  3T3-­‐‑L1  (41,42).  Other  groups  
use  primary  ASCs  isolated  from  human  patient  adipose  tissue  (37,  43-­‐‑44).  There  are  
advantages  of  using  human  ASCs  because  its  use  makes  it  possible  to  specifically  study  
breast  adipose  tissue  involved  in  differing  states  of  carcinogenesis.    
1.4.1.2  Adipose  Stromal  Cells  
To  date,  the  Seewaldt  lab  has  18  characterized  ASC  lines  and  over  30  additional  
lines  that  have  yet  to  be  characterized.  Adipose  stromal  cells  are  isolated  from  primary  
patient  adipose  tissue  and  characterized  by  their  ability  to  differentiate  and  their  
cytokine  profile  in  conditioned  media.  Freshly  isolated  ASCs  are  maintained  in  culture  
until  multiple  passages  are  frozen  at  -­‐‑80oC.  
Breast  adipose  stromal  cells  are  utilized  because  of  their  importance  to  the  breast  
microenvironment.  Thus,  all  of  the  ASC  lines  are  derived  from  prophylactic  
mastectomies  or  mastectomies  as  a  result  of  a  cancer  diagnosis.  Depending  on  the  nature  
of  the  surgery  and  the  ability  to  successfully  isolate  ASCs,  there  are  ASC  lines  for  both  
breasts  from  the  same  women,  allowing  for  potential  studies  comparing  diseased  breast  
tissue  to  non-­‐‑diseased  breast  tissue.    
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1.4.1.3  ASC  Characterization  
The  18  ASC  lines  of  the  study  came  from  a  panel  of  women  whose  body  mass  
index  (BMI)  ranged  from  22-­‐‑44  and  whose  age  ranged  from  32-­‐‑45.  Three  of  the  women  
were  also  BRCA1  mutation  carriers.  Two  ASC  lines  were  produced  from  each  breast  of  
one  of  the  women  carrying  a  BRCA1  mutation,  thus  generating  four  lines  that  carry  a  
BRCA1  mutation.    
To  characterize  these  the  ASCs,  these  cell  lines  were  differentiated  into  
adipocytes  and  osteocytes  to  show  pluripotency,  which  is  characteristic  of  ASCs.  The  IL6  
levels  were  then  measured  in  conditioned  media  using  ELISA  (Figure  1).    Not  all  of  the  
cell  lines  were  differentiated  into  either  adipocytes  or  osteocytes.  The  inability  to  
differentiate  could  be  due  to  different  factors.  Firstly,  fibroblasts  could  have  grown  out  
of  the  ASC  isolation.  Fibroblasts  are  visually  the  same  as  ASCs,  and  both  have  similar  
cell  surface  markers,  which  make  them  impossible  to  sort.  One  way  to  test  if  there  is  
fibroblast  contamination  is  to  quantify  the  collagen  mRNA  in  the  non-­‐‑differentiating  
ASCs.  Fibroblasts  will  upregulate  collagen  mRNA  while  ASCs  will  not.  Secondly,  the  
ASCs  may  not  have  the  ability  to  differentiate  because  of  unforeseen  signaling  that  
inhibits  ASC  differentiation.  For  example,  TGF-­‐‑β  inhibits  ASCs  from  differentiating  into  
adipocytes  (45).  Thus,  in  order  to  elucidate  why  all  of  the  cells  did  not  differentiate  








Figure  1:  Adipose  stromal  cell  characterization  
  
   Adipose  stromal  cells  are  isolated  from  breast  adipose  tissue  of  women  who  are  
at  high  risk  for  breast  cancer  yet  are  without  disease.  A)  Bright  field  images  of  ASCs  
from  three  different  patients  in  their  undifferentiated  form,  differentiated  into  
adipocytes  and  stained  with  Oil-­‐‑Red-­‐‑O,  or  differentiated  into  osteocytes  and  stained  
with  Alizarin-­‐‑Red.  B)  Characterization  of  secreted  IL6  levels  from  14  primary  ASC  lines  
generated.  Note  the  varying  range  of  IL6  production  from  cell  lines.  4  of  the  5  highest  
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The  measured  IL6  levels  in  14  of  the  18  characterized  ASC  cell  lines  ranged  from  
1  ng/mL  to  almost  10  ng/mL  (Figure  1).  Mature  adipocytes  and  preadipocytes  have  been  
reported  to  secrete  IL-­‐‑6  (13-­‐‑15,  35-­‐‑37).  Additionally,  mature  adipocytes  and  
preadipocytes  secret  other  cytokines  (13,  35-­‐‑36).  A  RayBiotech  Human  Inflammatory  
Cytokine  Array  and  a  Human  Growth  Factor  Array  were  screened  with  ASC-­‐‑
conditioned  media  to  determine  which  cytokines  and  growth  factors  were  secreted  in  
addition  to  IL6.  There  were  no  measurable  growth  factors  secreted  into  the  media,  
although  multiple  groups  reported  ASCs  secreting  VEGF,  HGF,  and  M-­‐‑CSF  into  the  
media  (13,  39).    The  Human  Inflammatory  Cytokine  Array  did  confirm  the  presence  of  
IL6  and  IL8  (Figure  2).    Two  other  cytokines  were  present:  tissue  inhibitor  of  
metalloproteinases  2  (TIMP-­‐‑2),  and  monocyte  chemoattractant  protein-­‐‑1  (MCP-­‐‑1).  TIMP-­‐‑
2  inhibits  metalloproteinases  and  MCP-­‐‑1  was  discovered  as  a  chemokine  for  monocytes  
(46-­‐‑47).  There  was  no  measurable  IL1β  or  TNFα  (Figure  2).  Published  studies,  however,  
have  shown  that  both  of  these  cytokines  are  secreted  by  ASCs  (13,  39).    
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Figure  2:  Adipose  stromal  cell  cytokine  characterization  
  
   Two  RayBiotech  Cytokine  Arrays  were  used  to  characterize  the  ASC-­‐‑conditioned  
media.  Human  Inflammatory  Cytokine  Array  is  pictured  above.  Each  of  the  six  
conditioned  media  had  measureable  levels  of  IL6,  IL8,  MCP-­‐‑1,  and  TIMP-­‐‑2.  The  
remaining  dots  were  positive  controls.  The  Human  Growth  Factor  Array  did  not  
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A  Luminex®  Multiplex  Cytokine  Assay  was  performed  to  confirm  quantitatively  
the  levels  of  IL6,  IL8,  and  MCP-­‐‑1,  and  to  confirm  the  absence  of  TNFα,  TGFβ,  and  IL1β.  
This  method  uses  less  conditioned  media,  is  more  sensitive,  and  has  a  broader  range  
allowing  for  detection  of  lower  and  higher  concentrations  of  cytokine  than  an  ELISA.  
The  data  confirmed  the  presence  of  IL6,  IL8,  and  MCP-­‐‑1,  and  they  provided  a  
quantitative  measurement  of  each  cytokine  present  in  the  respective  ASC-­‐‑conditioned  
media  (Figure  3).  The  data  also  confirmed  the  absence  of  TNFα,  TGFβ  (Figure  3),  and  
IL1β  (data  not  shown).    
Primary  adipose-­‐‑conditioned  media  were  measured  for  the  levels  of  IL6,  IL8,  and  
MCP-­‐‑1  using  the  multiplex  assay  to  show  that  the  ASCs  are  producing  levels  of  
cytokines  similar  to  those  produced  by  primary  adipocytes.  The  IL6  and  IL8  produced  a  
wide  range  of  concentrations  across  the  primary  adipose-­‐‑conditioned  media  samples,  
but  MCP-­‐‑1  had  a  much  smaller  range  of  concentrations  (Figure  3).  IL6  and  IL8  produced  
by  the  ASCs  fell  within  the  range  of  IL6  and  IL8  concentrations  produced  by  the  primary  
adipose  tissue.  The  MCP-­‐‑1  in  the  ASC-­‐‑conditioned  media  was  approximately  50%  of  the  
MCP-­‐‑1  produced  by  the  primary  adipose  tissue.    
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Figure  3:    Conditioned  media  cytokine  quantification  using  Luminex®  Multiplex  
Cytokine  Assay    
  
   Luminex®  Multiplex  Cytokine  Assay  was  used  to  quantify  the  amount  of  
cytokines  present  in  conditioned  media  and  to  verify  the  absence  of  specific  cytokines.  
A)  The  multiplex  data  confirms  that  the  adipose  stromal  cell  conditioned  media  do  
contain  IL6,  IL8  and  MCP-­‐‑1,  and  that  they  do  not  contain  TNFα  or  TGFβ.  B)  
Conditioned  media  taken  directly  from  adipose  cubes  incubated  in  media  for  24  hours  
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1.4.1.4  Optimizing  ASC-­‐‑conditioned  Media  
Adipose  stromal  cell  conditioned  media  has  been  used  extensively  in  vitro  with  
transformed  cells.  The  use  of  ASC-­‐‑conditioned  media  with  most  transformed  cells  is  
simple  because  both  cell  types  are  grown  in  media  containing  fetal  bovine  serum  (FBS).  
Non-­‐‑transformed  cells  are  not  grown  in  media  containing  FBS.  MCF10A  cells,  for  
example,  are  grown  in  media  containing  adult  horse  serum  (HS),  which  does  not  have  
the  same  growth  factors  as  FBS.  MCF10A  is  a  non-­‐‑transformed,  spontaneously  
immortalized  epithelial  cell  line  derived  from  a  woman  who  had  fibrocystic  disease  (48).  
It  is  a  widely  used  and  well-­‐‑characterized  epithelial  cell  line.  MCF10A  is  an  ideal  non-­‐‑
transformed,  mammary  epithelial  cell  model  because  of  its  ability  to  undergo  EMT  and  
its  use  in  a  3D  modeling  system  (26,  33,  60,  63).    
Adipose  stromal  cells  were  tested  to  determine  if  they  could  be  grown  with  horse  
serum  instead  of  FBS.  The  cells  were  grown  in  DMEM  with  5%  HS  or  DMEM/F12  with  
5%  HS,  and  their  growth  was  measured  by  an  MTT  viability  assay.  The  results  of  the  
experiment  suggest  that  horse  serum  retarded  the  growth  of  ASCs  (Figure  4).  There  
were  also  fewer  visible  cells  in  the  DMEM/F12  with  5%  HS  condition.  When  measured  
using  a  RayBiotech  dot  array,  the  cells  in  the  horse  serum  still  produced  the  same  
cytokine  profile  as  those  grown  in  FBS  (Figure  4).  Though  the  cells  produced  a  similar  
cytokine  profile,  the  horse  serum  prevented  the  differentiation  of  the  ASCs  into  
adipocytes  or  osteocytes  (Figure  5).  The  cells  grown  in  DMEM  with  5%  HS  were  not  
stained  by  Oil-­‐‑Red-­‐‑O  or  Alizarin  Red,  indicating  that  they  did  not  undergo  adipogenesis  
or  osteogenesis  respectively.  The  cells  grown  in  DMEM/F12  with  5%  HS  lifted  from  the  
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plate  during  the  incubation  in  both  differentiation  medias.  Thus,  data  were  not  acquired  
from  DMEM/F12  with  5%  HS  condition  (Figure  5).  Therefore,  moving  forward,  











	  	   16  
  
  
Figure  4:  Horse  serum  slows  the  growth  of  adipose  stromal  cells.  
  
   Adipose  stromal  cells  are  cultured  in  DMEM  salts  media  with  high  glucose  and  
10%  FBS.  Non-­‐‑transformed,  mammary  epithelial  cells,  MCF10As,  are  grown  in  
DMEM/F12  supplemented  with  horse  serum  and  additional  growth  factors.  ASCs  were  
tested  to  determine  if  they  could  be  grown  under  the  same  conditions  as  MCF10A  cells.  
A)  An  MTT  assay  measured  ASCs  grown  under  three  different  conditions.  The  presence  
of  horse  serum  (HS)  significantly  retards  cell  growth.  B)  Additionally,  brightfield  images  
of  the  cell  numbers  at  the  end  of  the  nine  days  show  how  few  cells  were  in  either  horse  
serum  condition.  C)  ASCs  produced  IL6,  IL8,  MCP-­‐‑1  and  TIMP-­‐‑2  under  all  conditions  
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Figure  5:  Horse  serum  prevents  the  differentiation  of  ASCs  into  adipocytes  and  
osteocytes  
  
   ASCs  were  seeded  at  the  same  confluency.  Once  the  control  cells  (DMEM  10%  
FBS)  reached  100%  confluency,  the  cells  were  treated  with  adipogenic,  osteogenic,  or  
normal  growth  media  for  suggested  length  of  differentiation.  Adipocytes  were  stained  
with  Oil-­‐‑Red-­‐‑O  and  osteocytes  were  stained  with  Alizarin  Red.  The  DMEM  containing  
horse  serum  (HS)  did  not  differentiate  into  mature  adipocytes  or  osteocytes.  No  data  
were  available  for  DMEM/F12  with  horse  serum  because  the  sparse  cells  lifted  during  
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1.4.1.5  ASC  &  MCF10A  Co-­‐‑culture  
When  cultured  with  ASC-­‐‑conditioned  media  for  two  weeks,  MCF10A  cell  
morphology  changed.  Furthermore,  ASC-­‐‑conditioned  media  increased  Vimentin  by  
western  blot,  and  increased  wound  closure  by  wound  healing  migration  assay  (Figure  
6).    
The  ASC-­‐‑conditioned  media  had  multiple  factors  present:  IL6,  IL8,  and  MCP-­‐‑1.  
IL6  has  been  shown  to  induce  EMT  in  transformed  breast  cells  (27,  37).  Blocking  IL6,  
using  antibodies,  from  the  conditioned  media  did  not  inhibit  Vimentin  protein  increase,  
and  treating  with  recombinant  IL6  did  not  increase  Vimentin  protein.  Additionally,  IL8  
has  been  shown  to  induce  EMT  in  breast  cancer  cell  lines  (30).  Treatment  of  MCF10A  
cells  with  recombinant  IL8,  however,  did  not  induce  Vimentin  protein.  MCP-­‐‑1  has  not  
been  shown  to  induce  EMT  in  mammary  epithelial  cells,  but  MCP-­‐‑1  in  kidney  and  
peritoneum  EMT  has  been  studied.  Because  of  its  role  in  kidney  and  peritoneum  EMT,  
MCP-­‐‑1  may  potentially  induce  EMT  in  mammary  epithelial  cells.      
Quantitative  measurement,  using  a  Luminex®  Multiplex  assay,  of  the  24  hour  
conditioned  media  taken  off  of  the  MCF10As  at  day  7  and  day  14  revealed  an  increase  in  
the  concentration  of  IL8  and  MCP-­‐‑1  in  the  media  (Figure  7).  ASC-­‐‑conditioned  media  
contributes  paracrine  MCP-­‐‑1,  but  these  data  suggest  that  the  MCF10As  begin  secreting  
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Figure  6:  ASC-­‐‑conditioned  media  induces  Vimentin  and  increases  migration  
  
   MCF10A  cells  were  grown  in  DMEM/F12  5%  HS  (base  media),  DMEM  10%  FBS,  
and  ASC-­‐‑conditioned  media  for  two  weeks.  A)  Conditioned  media  induced  Vimentin  
protein  expression  in  MCF10A  cells.  B)  Conditioned  media  increased  migration  by  

























Figure  7:  Long-­‐‑term  co-­‐‑culture  with  ASC-­‐‑conditioned  media  induces  IL8  and  MCP-­‐‑1  
secretion  by  MCF10A  cells  
  
   Passage-­‐‑matched  conditioned  media  saved  either  before  they  were  used  or  24  
hours  after  they  were  used  on  cells.  Media  came  from  time  points  as  indicated  and  were  
measured  using  Luminex®  Multiplex  Cytokine  Array  quantitative  technology.  MCF10A  
cells  grown  in  conditioned  media  from  two  different  ASC  lines  both  secreted  IL8  and  
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1.5 Monocyte Chemoattractant Protein-1 
Monocyte  chemoattractant  protein-­‐‑1  is  a  small  cytokine  that  belongs  to  the  CC  
family  of  chemokines.  Chemokines  are  chemotactic  cytokines  whose  main  function  is  to  
regulate  cell  trafficking  and  are  secreted  in  response  to  signals  such  as  proinflammatory  
cytokines  (49).  This  chemokine  induction  could  explain  why  the  MCF10As  would  start  
secreting  MCP-­‐‑1  and  IL8  after  treatment  with  ASC-­‐‑conditioned  media,  which  contain  
proinflammatory  cytokines.  Chemokines  are  grouped  into  two  main  functional  
subfamilies:  inflammatory  and  homeostatic.  Inflammatory  chemokines  control  the  
recruitment  of  leukocytes  to  sites  of  injury  and  inflammation.  Homeostatic  chemokines  
perform  housekeeping  functions  by  navigating  leukocytes  between  secondary  lymphoid  
organs  and  within  the  bone  marrow  and  thymus  (49).      
Outside  of  their  normal  immune  roles,  chemokines  are  involved  in  a  number  of  
diseases:  autoimmune  disorders,  pulmonary  disease,  transplant  rejection,  vascular  
disease,  and  cancer.  MCP-­‐‑1  has  been  demonstrated  as  a  potential  intervention  point  for  
the  treatment  of  multiple  sclerosis,  rheumatoid  arthritis,  and  insulin-­‐‑resistant  diabetes  
(49).    Additionally,  MCP-­‐‑1  has  been  implicated  in  kidney  injury,  fibrosis,  and  EMT,  and  
MCP-­‐‑1  has  been  implicated  in  peritoneal  fibrosis  and  EMT.  (78-­‐‑79,  90-­‐‑93).  While  it  is  
amongst  the  most  studied  members  of  the  chemokine  family,  the  role  of  MCP-­‐‑1  in  breast  
cancer  has  only  recently  been  brought  to  light.    
MCP-­‐‑1  is  a  potent  regulator  of  the  migration  and  infiltration  of  monocytes  and  
macrophages.  It  is  produced  by  a  variety  of  cell  types,  either  constitutively  or  after  
induction  by  cytokines  or  growth  factors.  These  include  endothelial,  fibroblastic,  
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epithelial,  smooth  muscle,  mesangial,  astrocytic,  monocytic,  and  microglial  cells  (49).  An  
increase  in  adipose  tissue  is  a  major  contributor  to  increased  MCP-­‐‑1  levels  in  the  human  
body.  Multiple  groups  have  shown  that  circulating  concentrations  of  MCP-­‐‑1  correlated  
positively  with  adiposity  (50-­‐‑51).  It  was  also  shown  that  insulin  increased  the  
concentration  levels  of  MCP-­‐‑1  secreted  by  adipocytes  (50).  Taken  together,  obesity  is  
associated  with  increased  MCP-­‐‑1.  
1.5.1 MCP-1 Signaling 
Chemokines  signal  cells  by  binding  and  activating  G-­‐‑protein-­‐‑coupled  receptors  
(GPCRs)  (49).  The  primary  receptor  for  MCP-­‐‑1  is  CCR2  (49),  but  models  of  CCR2  knock-­‐‑
out  mice  and  cells  used  from  those  mice  suggest  other  possible  receptors  (52-­‐‑53).    The  
chemokine  receptor  CCR4  has  been  shown  to  bind  MCP-­‐‑1  and  mediate  migration  in  
cells  lacking  CCR2  (54-­‐‑55).  Both  transformed  and  non-­‐‑transformed  breast  cell  lines  
express  varying  levels  of  CCR2  protein  and  mRNA  (Figure  8).  Upon  binding  together  of  
MCP-­‐‑1  and  CCR2,  the  mitogen–activated  protein  kinase  (MAPK)  signaling  pathway  is  
activated  through  Ras/Raf/Mek  signaling.  Activation  of  Ras/Raf/Mek  signaling  results  in  
phosphorylation  of  Erk1/2  at  T202/Y204  (53,  56-­‐‑58).  MCF10A  cells  treated  with  MCP-­‐‑1  
rapidly  phosphorylate  Erk1/2  at  T202/Y204,  but  this  activation  is  lost  by  24  hours  (Figure  
9).  IL6  is  an  inflammatory  cytokine  capable  of  activating  Erk  in  vitro  (80).  IL6,  however,  
activates  JAK-­‐‑STAT  signaling,  which  results  in  Stat3  phosphorylation  at  Y705  in  
MCF10A  cells  (Figure  9).    
Taken  together,  MCP-­‐‑1  is  an  inflammatory  chemokine  that  correlates  with  
obesity,  activates  Erk  MAPK  signaling,  and  induces  kidney  and  peritoneum  EMT.  It  
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remains  to  be  determined  if  MCP-­‐‑1  directly  induces  EMT  in  non-­‐‑transformed,  
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Figure  8:  CCR2  quantification  
  
   The  data  above  quantify  the  chemokine  receptor  CCR2  in  several  breast  cell  lines  
by  A)  western  blotting  and  B)  qRT-­‐‑PCR.  15hT  is  an  hTERT  immortalized  non-­‐‑
transformed  human  mammary  epithelial  cell  (HMEC).  There  are  two  MCF10A  cell  lines  
compared  here.  While  both  are  MCF10A,  their  culturing  history  has  resulted  in  modified  
CCR2  levels.  MCF7  cells  are  from  a  luminal  breast  tumor  while  MDA-­‐‑MB-­‐‑231  and  435  






















	  	   25  
  
  
Figure  9:  Cytokine  signaling  pathway  activation  
  
   MCF10A  cells  were  treated  with  either  20  ng/mL  IL6  or  MCP-­‐‑1,  and  protein  
lysates  were  extracted  at  the  time  point  indicated.  A)  IL6  binds  IL6  receptor,  signals  
through  GP130  and  rapidly  phosphorylates  STAT3  at  Y705.  B)  MCP-­‐‑1  binds  CCR2,  
activating  MAPK  signaling  through  Ras/Raf/Mek,  which  results  in  phosphorylation  of  

























	  	   26  
2 Materials and Methods 
2.1 Antibodies and Reagents 
   Anti-­‐‑Vimentin  (Rabbit),  -­‐‑p44/42  MAPK,  -­‐‑phospho  p44/42  MAPK(T202/Y204),  -­‐‑
αTubulin,  -­‐‑Cleaved  Caspase  3,  -­‐‑CCR2,  -­‐‑βcatenin,  -­‐‑Stat3,  and  -­‐‑phospho  STAT3(Y705)  
were  purchased  from  Cell  Signaling.  Anti-­‐‑Vimentin  (Mouse),  -­‐‑Ncadherin,  and  -­‐‑
Ecadherin,  were  purchased  from  BD  Bioscience.  Anti-­‐‑Integrin  α6,  or  HRP  conjugated  
Actin,  donkey  anti  rabbit,  and  donkey  anti  mouse  were  purchased  from  Santa  Cruz.  
Alexa  Fluor  anti-­‐‑mouse  594  nm  and  anti-­‐‑rabbit  488  nm  were  purchased  from  Life  
Science  Technologies.  APC,  APC-­‐‑CD44,  PE,  and  PE-­‐‑CD24  were  purchased  from  BD  
Pharmigen.    
   Recombinant  human  IL6,  IL8,  MCP-­‐‑1,  and  MMP-­‐‑2;  and  Quantikine  Human  IL6  
ELISA  were  purchased  from  R&D  Systems.  Human  TGF-­‐‑β1,  TNFα,  and  PD98059  were  
purchased  from  Cell  Signaing.  Thiazolyl  Blue  Tetrazolium  Bromide  and  Eosin  Solution  
were  purchased  from  Sigma  Aldrich.  Hematoxylin  was  purchased  from  Lerner  
Laboratories.  Normal  goat  serum  and  Immunofluorescence  mounting  solution  were  
purchased  from  Vector.  DAPI,  NuPAGE  4-­‐‑12%  Bis-­‐‑Tris  Gel,  NuPAGE  MOPS  SDS  
Running  Buffer,  Novex  10%  Zymogram  (Gelatin)  Gel,  Tris-­‐‑Glycine  SDS  Running  Buffer,  
Novex  Zymogram  Renaturing  Buffer,  Novex  Zymogram  Developing  Buffer,  and  Tris-­‐‑
Glycine  Sample  Buffer  were  purchased  from  Life  Science  Technologies.  8.0  micron,  6.5  
mm  PET  membrane  inserts  were  purchased  from  COSTAR.  Transcriptor  First  Strand  
cDNA  synthesis  kit  was  purchased  from  Roche.  RT2  SYBR  Green  qPCR  Mastermix,  
Prevalidated  human  CCR2  qPCR  primers,  and  RNeasy  Plus  Mini  Kit  were  purchased  
	  	   27  
from  Qiagen.  Milliplex  plates  for  Luminex  were  purchased  from  EMD  Millipore.  
Growth  factor  reduced  Matrigel  and  Dispase  were  purchased  from  BD  Bioscience.  Bio-­‐‑
Safe  Coomasie  protein  stain  was  purchased  from  BioRad.    
   DMEM,  DMEM/F12,  FBS,  and  0.5%  Trypsin-­‐‑EDTA  were  purchased  from  Gibco.  
Hydrocortisone  and  Insulin  were  purchased  from  Sigma  Aldrich.  Cholera  Toxin  was  
purchased  from  Calbiochem  and  EGF  was  purchased  from  Peprotech.    
2.2 ASC-conditioned Media 
   Adipose  Stromal  Cells  were  seeded  at  1.4  x  106  in  20.6  mL  of  DMEM  media  
supplemented  with  10%  FBS  in  a  T75  flask.  After  72  hours,  the  media  was  removed  from  
the  cells  and  spun  down  at  1200  rpm.  The  supernatant  was  frozen  at  -­‐‑80oC  in  10  mL  
aliquots  and  never  thawed  more  than  twice.    
2.3 Long-term 2D Co-culture 
   MCF10A  cells  were  seeded  at  6  x  105  in  3  mL  of  media  in  a  T25  flask.  The  medias  
the  cells  were  cultured  in  are  described  in  Table  1.  The  media  were  changed  every  24  
hours  for  the  length  of  the  experiment.  Every  three  days  the  cells  were  reseeded  (Figure  
10).  On  day  12,  MCF10A  cells  were  seeded  at  4  x  105  in  2mL  media  in  duplicate  in  a  6  
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Table  1:  Medias  used  in  long-­‐‑term  2D  co-­‐‑culture  
  
   Listed  below  are  the  nine  conditions  used  in  the  2D  long-­‐‑term  co-­‐‑culture  
experiment.  Both  TGF-­‐‑β1  and  TNFα  were  used  as  positive  controls  for  EMT.  The  TGF-­‐‑
β1  control  was  removed  after  the  four  days  because  the  cells  were  arresting  and  TNFα  
was  a  better  long-­‐‑term  control.  All  medias  were  supplemented  with  EGF,  
















DMEM/F12  +  5%  Horse  Serum   DMEM  +  10%  FBS  
Untreated   Untreated  
2ng/mL  TGF-­‐‑β1   2ng/mL  TGF-­‐‑β1  
4ng/mL  TNFα   4ng/mL  TNFα  
20ng/mL  MCP-­‐‑1   20ng/mL  MCP-­‐‑1  
   ASC-­‐‑conditioned  Media  




Figure  10:  Schematic  of  long-­‐‑term  2D  co-­‐‑culture  work  flow  
  
   The  cells  were  seeded  on  Day  0  and  reseeded  at  days  3,  6,  9  and  12  to  prevent  the  
MCF10As  from  becoming  confluent.  The  media  was  changed  every  24  hours  to  maintain  
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2.4 Long-term 3D Culture 
   MCF10A  cells  were  seeded  at  5  x  102  in  200µμL  assay  media  per  well  in  an  8  well  
chamber  slide  coated  with  100µμL  growth  factor  reduced  Matrigel.  Acini  were  allowed  to  
form  for  14  days  with  regular  media  changes  every  2-­‐‑3  days.  On  the  day  14,  the  media  
was  removed  and  replaced  with  fresh  media  containing:  5ng/mL  MCP-­‐‑1;  10µμM  
PD98059;  MCP-­‐‑1  &  PD98059;  or  nothing  (untreated  control).    These  medias  were  
changed  every  24  hours  for  4  days.  On  day  18,  the  chamber  slides  were  processed  for  
immunofluorescence.    
2.5 Migration & Invasion Assays 
2.5.1 Boyden Chamber Migration Assay 
   MCF10A  cells  were  seeded  at  2  x104  in  100µμL  of  base  media  or  base  media  
containing  10µμM  PD98059  into  the  upper  chamber  of  a  6.5  mm  8µμm  PET  Boyden  
Chamber  and  allowed  to  incubate  at  room  temperature  for  30  min.  The  upper  chamber  
was  then  placed  into  a  well  containing  600µμL  of  base  media  containing:  5ng/mL  MCP-­‐‑1;  
10µμM  PD98059;  MCP-­‐‑1  &  PD98059;  or  nothing  (untreated  control).  The  Boyden  
Chambers  were  placed  at  37oC,  5%  CO2,  and  humidity  for  21  hours.    
   After  the  overnight  incubation,  the  upper  chambers  were  removed  and  washed  
twice  with  PBS  and  fixed  in  2%  buffered  formalin  for  10  min.  The  cells  inside  the  upper  
chamber  were  removed  with  a  cotton  swab.  The  cells  on  the  bottom  of  the  membrane  
were  stained  for  10  min  in  hematoxylin,  washed  3  times  in  dH2O,  counter  stained  for  10  
min  in  eosin,  and  washed  3  times  in  dH2O.  Cells  were  then  imaged  at  10x  on  a  Zeiss  
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inverted  light  microscope.  Five  images  per  membrane  were  taken  and  the  average  
number  of  cells  per  field  of  view  were  recorded.    
2.5.2 Spheroid Gel Invasion Assay  
MCF10A  cells  were  seeded  at  2.4  x  104  cells  per  well  in  a  6  well  plate  embedded  
in  800µμL  of  growth  factor  reduced  Matrigel.  2  mL  of  assay  media  was  added  to  each  
well  after  the  gels  polymerized  and  speroids  were  allowed  to  form  for  14  days  with  
regular  media  changes  every  2-­‐‑3  days.  On  the  day  14,  the  media  was  removed  and  
replaced  with  fresh  media  containing:  5ng/mL  MCP-­‐‑1;  10µμM  PD98059;  MCP-­‐‑1  &  
PD98059;  or  nothing  (untreated  control).    These  medias  were  changed  every  24  hours  for  
4  days.  On  day  18,  spheroids  were  imaged  using  light  microscopy.  The  media  was  spun  
down  at  1200  rpm  and  the  supernatant  was  used  for  gelatin  zymography.    
2.6 Immunofluorescence 
     Media  was  removed  from  each  chamber  well  and  the  cells  were  washed  once  
with  ice-­‐‑cold  PBS.  Cells  were  then  fixed  in  ice-­‐‑cold  methanol  and  incubated  at  -­‐‑20oC  for  
10  min.  Cells  were  then  washed  twice  with  room  temperature  PBS  and  incubated  in  
blocking  solution  (5%  BSA,  0.05%  Triton,  PBS,  1:500  normal  goat  serum)  for  30  min  at  
room  temp.  Cells  were  then  incubated  in  primary  antibody  overnight  at  4oC  while  
rocking.    
   The  following  day,  cells  were  allowed  to  warm  to  room  temperature  for  60  min  
and  washed  twice  with  PBS.  Secondary  antibodies  were  added  at  1:400  in  PBS  and  
incubated  for  60  min  at  room  temperature  in  the  dark.  The  secondary  antibodies  were  
then  removed  and  the  cells  were  stained  with  DAPI  (1:5000  in  PBS)  for  3  min  at  room  
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temperature  and  then  washed  twice  with  PBS.  Cells  were  then  mounted  using  Vector  
immunofluorescent  mounting  solution  and  a  coverslip,  dried,  and  stored  at  4oC  prior  to  
imaging.  All  images  were  taken  with  a  Zeiss  upright  confocal  microscope.    
2.7 Gelatin Zymography 
   Media  was  removed  from  spheroid  gel  invasion  assay  after  24  hours  of  
conditioning  on  the  last  day  of  treatment,  spun  down,  and  stored  at  -­‐‑80oC  or  used  
immediately.    15µμL  of  conditioned  media  was  added  to  15µμL  of  2x  Tris-­‐‑Glycine  SDS  
loading  buffer  and  25µμL  of  sample  was  loaded  into  each  lane  of  a  10  well,  1.0  mm,  
Novex  Zymogram  (Gelatin)  gel.  One  lane  contained  MMP-­‐‑2  recombinant  protein  as  a  
positive  control.  The  samples  were  run  at  150V  until  the  dye  front  migrated  off  the  gel.  
The  gel  was  removed  an  incubated  in  Novex  Zymogram  renaturing  buffer  for  60  min  at  
room  temperature  followed  by  an  incubation  in  Novex  Zymogram  developing  buffer  for  
60  min  at  room  temperature.  After  the  last  incubation,  the  developing  buffer  was  
replaced  and  the  gel  was  incubated  for  18  hours  at  37oC  with  humidity.  The  following  
day,  the  gel  was  washed  in  dH2O  and  then  stained  for  60  min  in  Bio-­‐‑Safe  Coomasie  
protein  stain.  The  gel  was  then  destained  in  dH2O  for  60  min  and  imaged  using  a  Kodak  
imager.    
2.8 ASC Lineage Induction 
   ASCs  were  plated  in  6  well  plates  and  grown  to  confluency.  For  adipogenesis,  
the  growth  media  was  removed  and  replaced  with  adipogenic  media  (DMEM,  10%  FBS,  
0.5  mM  IBMX,  1  µμM  dexamethasone,  10  µμM  insulin,  200  µμM  indomethacin)  for  two  
weeks  changing  the  media  every  three  days.  To  verify  adipogenesis,  cells  were  stained  
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with  Oil-­‐‑Red-­‐‑O.  For  osteogenesis,  the  growth  media  was  removed  and  replaced  with  
osteogenic  media  (DMEM,  10%  FBS,  0.1  µμM  dexamethasone,  50  µμM  L-­‐‑ascorbic  acid  2-­‐‑
phosphate,  and  10  mM  β-­‐‑glycerophosphate)  for  three  weeks  changing  the  media  every  
three  days.  To  verify  osteogenesis,  the  cells  were  stained  with  Alizarin  Red.    
2.9 Direct 3D Co-culture 
   ASCs  were  seeded  and  grown  to  confluency  in  4  well  chamber  slides.  Once  they  
were  confluent,  250  µμL  Matrigel  was  placed  over  the  cells  and  solidified  at  37oC.  
MCF10A  cells  were  then  seeded  at  1  x  103  in  500  µμL  of  media.  The  cells  were  allowed  to  
grow  for  two  weeks  with  fresh  media  every  2-­‐‑3  days.  After  14  days,  the  cells  were  
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3 Results 
3.1 MCP-1 does not induce EMT in MCF10A cells in 2D culture 
   A  13-­‐‑day  culture  was  performed  to  determine  whether  MCP-­‐‑1  induced  EMT  in  
MCF10A  cells.  After  13  days  of  culturing,  the  positive  control  TNFα  abolished  the  
expression  of  E-­‐‑cadherin  in  the  MCF10A  cells  (Figure  11).  TNFα  did  not  increase  
Vimentin  or  N-­‐‑cadherin  compared  to  the  DMEM  10%  FBS  plus  growth  factor  untreated  
control.  ASC-­‐‑conditioned  media  also  did  not  increase  Vimentin,  which  was  observed  in  
the  initial  co-­‐‑culture.  ASC-­‐‑conditioned  media  did  decrease  E-­‐‑cadherin  compared  to  the  
DMEM  10%  FBS  control.  The  absence  in  Vimentin  change  could  be  due  to  the  high  basal  
levels  of  Vimentin  in  the  cells  after  the  culturing  process.  Both  the  TNFα  and  the  ASC-­‐‑
conditioned  media  decreased  the  epithelial  marker,  E-­‐‑cadherin.  MCP-­‐‑1  treatment  did  
not  decrease  E-­‐‑cadherin  compared  to  the  DMEM  10%  FBS  control,  nor  did  it  increase  
Vimentin  or  N-­‐‑cadherin.  Therefore,  in  2D  culture,  MCP-­‐‑1  does  not  induce  EMT.  
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Figure  11:  In  2D  culture,  MCP-­‐‑1  does  not  decrease  E-­‐‑cadherin  in  13  days  
  
   MCF10A  cells  treated  for  13  days  with  MCP-­‐‑1  did  not  decrease  E-­‐‑cadherin  
compared  to  the  DMEM  10%  FBS  +  Growth  Factors  (GF)  control.  TNFα  treatment  
eliminated  E-­‐‑cadherin  while  ASC-­‐‑conditioned  media  decreased  E-­‐‑cadherin  compared  to  
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3.2 MCP-1 rapidly decreases E-cadherin in 3D culture  
Breast  epithelial  cells  in  vivo  do  not  grow  in  a  flat  monolayer  on  plastic.  Breast  
epithelial  cells  in  vivo  engage  with  the  extracellular  matrix  (ECM),  are  polarized,  and  
form  3D  branching  structures.  MCF10A  cells  are  used  to  form  3D  acini  with  hollow  
lumen  when  grown  in  ECM  to  model  in  vivo  characteristics.  Therefore,  MCF10A  acini  
were  treated  with  MCP-­‐‑1  to  test  whether  MCP-­‐‑1  could  induce  EMT  in  non-­‐‑transformed,  
mammary  epithelial  cells.  
The  fully  formed  lumens  of  MCF10A  acini  were  hollow.  The  MCF10A  cells  
expressed  plasma  membrane  localized  E-­‐‑cadherin  and  β-­‐‑catenin.  Additionally,  they  
weakly  expressed  Vimentin.  Lastly,  Integrin  α6  was  localized  to  the  basal  membrane,  
which  indicated  basal  polarity  (Figure  12).      
After  four  days  of  treatment  with  MCP-­‐‑1,  MCF10A  cells  rapidly  lost  E-­‐‑cadherin  
expression  (Figure  13).  Additionally,  MCP-­‐‑1  induced  the  loss  of  β-­‐‑catenin  expression,  
and  Integrin  α6  broke  down  around  the  protrusions  (Figure  13).    
Erk  signaling  is  linked  to  the  loss  of  E-­‐‑cadherin  expression  in  EMT  (61-­‐‑62).  The  
pharmacological  Erk  inhibitor  PD98059  was  used  to  test  whether  inhibition  of  Erk  
prevents  loss  of  E-­‐‑cadherin.  Pretreatment  with  PD98059  prevented  MCP-­‐‑1  induced  
phosphorylation  of  Erk1/2  at  T202/Y204  in  MCF10A  cells  (Figure  14).  Treatment  of  
MCF10A  acini  with  PD98059  alone  did  not  affect  the  morphology  of  the  acini,  nor  did  it  
alter  the  E-­‐‑cadherin  staining.  The  staining  of  β-­‐‑catenin  was  lost  when  treated  with  
PD98059,  but  Integrin  α6  still  stained  the  basal  pole  of  the  cells  in  the  acini  (Figure  13).    
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Pretreatment  of  MCF10A  acini  with  PD98059,  followed  by  co-­‐‑treatment  with  
MCP-­‐‑1  and  PD98059,  prevented  the  loss  of  E-­‐‑cadherin,  formation  of  projections,  and  the  
breakdown  of  Integrin  α6  (Figure  13).  Only  β-­‐‑catenin  was  not  restored,  and  this  staining  
was  lost  with  the  treatment  of  PD98059.  These  data  suggest  that  the  Erk  signaling  















Figure  12:  MCF10A  cells  form  hollow  acini  when  grown  in  Matrigel  
  
   MCF10A  cells  formed  a  hollow  lumen  when  grown  in  a  three-­‐‑dimensional  
matrix.  The  epithelial  cells  expressed  plasma  membrane  localized  E-­‐‑cadherin  and  
minimal  Vimentin.  They  also  expressed  plasma  membrane  localized  β-­‐‑catenin  and  
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Figure  13:  MCP-­‐‑1  decreases  E-­‐‑cadherin  and  β-­‐‑catenin  in  3D    
  
   MCF10A  cells  were  grown  to  form  acini  for  14  days  and  then  treated  for  four  
days  with  MCP-­‐‑1,  PD98059,  or  both.  MCP-­‐‑1  caused  a  decrease  in  E-­‐‑cadherin  while  
PD98059  prevented  loss  of  E-­‐‑cadherin  expression.  MCP-­‐‑1  also  caused  a  breakdown  of  
the  basal  polarity  marker  Integrin  α6  expression  and  a  loss  in  the  epithelial  marker  β-­‐‑
catenin.  The  Erk  inhibitor  PD98059  also  decreased  β-­‐‑catenin,  and  thus,  did  not  prevent  
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Figure  14:  PD98059  blocks  MCP-­‐‑1  induced  Erk1/2  phosphorylation  
  
   MCP-­‐‑1  induced  the  rapid  phosphorylation  of  Erk1/2,  but  this  was  blocked  by  the  
potent  Erk  inhibitor  PD98059  at  a  concentration  of  10  µμM.  A)  Western  blot  of  the  MCP-­‐‑1  
time  course.  B)  Quantification  of  relative  expression  of  Erk1/2  phosphorylation  over  the  
MCP-­‐‑1  time  course.  C)  Western  blot  of  the  PD98059  +  MCP-­‐‑1  time  course.  D)  
Quantification  of  relative  expression  of  Erk1/2  phosphorylation  over  the  PD98059  +  
MCP-­‐‑1  time  course.    
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While  the  cells  treated  with  MCP-­‐‑1  appear  to  have  lost  their  E-­‐‑cadherin  
expression,  it  is  possible  that  there  was  an  excess  of  apoptosis  in  the  E-­‐‑cadherin  
expressing  cells  as  a  result  of  treatment.  To  rule  this  out,  acini  that  went  through  the  
same  14-­‐‑day  growth  and  4-­‐‑day  treatment  process  were  dual-­‐‑stained  with  cleaved  
Caspase  3  to  indicate  apoptosis  and  Integin  α6  to  indicate  polarity  and  structure  (Figure  
15).    There  was  minimal  staining  for  cleaved  Caspase  3  in  all  imaged  acini.  This  includes  
MCP-­‐‑1,  PD98059,  MCP-­‐‑1  and  PD98059,  and  untreated  control.  Joan  Brugge’s  group  
showed  that  MCF10A  cells  will  undergo  apoptosis  to  form  the  hollow  lumen  (63).  
Therefore,  the  minimal  cleaved  Caspase  3  staining  that  occurred  could  be  the  remnants  
of  cells  clearing  the  lumen.    
In  summary,  MCP-­‐‑1  induced  the  loss  of  E-­‐‑cadherin  staining,  the  loss  of  β-­‐‑catenin  
staining,  and  the  loss  of  Integrin  α6  staining  surrounding  the  protrusions  in  MCF10A  
acini  grown  in  3D  culture.  Additionally,  inhibition  of  Erk  signaling  with  the  
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Figure  15:  MCP-­‐‑1  does  not  increase  apoptosis  within  the  acini  
  
   Acini  were  stained  with  cleaved  Caspase  3  to  rule  out  the  loss  of  E-­‐‑cadherin  
expressing  cells  by  increased  apoptosis.  All  acini  in  all  conditions  expressed  some  
cleaved  Caspase  3,  but  no  more  than  any  other  condition.  This  is  to  be  expected  as  
MCF10A  cells  apoptose  to  clear  the  lumen,  and  cleaved  Caspase  3  expression  may  
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3.3 MCP-1 induces migration in MCF10A cells 
A  Boyden  Chamber  migration  assay  was  used  to  determine  whether  MCP-­‐‑1  
induced  chemotaxis  of  MCF10A  cells.  Untreated  MCF10A  cells  did  migrate,  which  was  
expected  because  studies  have  shown  that  MCF10As  are  migratory  (33,  64).  MCP-­‐‑1,  
however,  caused  a  40%  increase  in  migration  of  the  MCF10A  cells  over  that  of  the  
untreated  controls  (Figure  16).    
   MAP  kinases  govern  cell  migration,  and  Erk  is  rapidly  phosphorylated  by  MCP-­‐‑
1  (65).  Therefore,  MCF10A  cells  pretreated  with  PD98059  were  tested  to  determine  
whether  they  would  migrate  toward  MCP-­‐‑1  (Figure  16).  When  Erk  signaling  was  
inhibited,  migration  towards  MCP-­‐‑1  was  significantly  inhibited.  These  data  suggest  that  
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Figure  16:  MCP-­‐‑1  induces  migration  in  MCF10A  cells  
  
   In  a  Boyden  Chamber  migration  assay,  there  was  a  40%  increase  in  migration  in  
MCF10A  cells  when  presented  with  MCP-­‐‑1  as  a  chemoattractant.  The  Erk  inhibitor  
PD98059  significantly  decreased  the  migration  of  the  cells  and  prevented  the  MCP-­‐‑1  
induced  migration.  Three  independent  experiments  were  conducted  with  two  transwell  
Boyden  Chambers  per  condition.  P  values  were  calculated  using  a  student  paired  T-­‐‑test  
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3.4 MCP-1 induces invasion in MCF10A cells 
   A  spheroid  gel  invasion  assay  was  used  to  test  whether  MCP-­‐‑1  induced  invasion  
in  MCF10A  cells.  In  this  assay,  non-­‐‑invasive  cell  lines  form  compact  spheroids  with  a  
distinct  border  when  imbedded  in  3D  ECM.  Invasive  cells  invade  the  surrounding  
matrix  and  display  outgrowth  from  the  spheroid.  Invasion  is  then  followed  by  live  cell  
imaging  (17).  
MCF10A  cells  imbedded  in  ECM  were  grown  for  14  days  followed  by  4  days  of  
continuous  treatment  every  24  hours.  Treatment  of  MCF10A  spheroids  with  MCP-­‐‑1  
induced  the  invasion  of  cells  away  from  the  spheroids  into  the  matrix  (Figure  17).  The  
distinct  borders  of  the  spheroids  were  lost  as  cells  invaded  the  matrix  and  the  cells  
invaded  as  clusters.  In  some  instances,  the  cells  passed  through  the  matrix  to  populate  
the  plastic  chamberwell  slide.    
   Pretreatment  of  MCF10A  spheroids  with  the  Erk  signaling  inhibitor  PD98059  
inhibited  matrix  invasion  (Figure  17).  Spheroids  maintained  their  distinct  borders  and  
showed  no  signs  of  invasion.  The  inhibition  of  matrix  invasion  by  PD98059  suggests  that  
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Figure  17:  MCP-­‐‑1  induces  invasion  of  cells  away  from  spheroid  and  into  ECM  
  
   MCF10A  spheroids  treated  with  MCP-­‐‑1  produced  outgrowth  of  cells  moving  
away  from  the  spheroids.  These  cells  invaded  the  Matrigel  ECM.  In  some  cases,  not  
pictured  here,  the  cells  invaded  the  matrix  to  the  plastic  bottom  of  the  chamber  slide  and  
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   In  order  for  the  MCF10A  cells  to  invade,  they  have  to  break  down  the  ECM  
surrounding  the  spheroid  (66).  This  is  accomplished  by  the  secretion  of  matrix  
metalloproteinases  (MMPs),  which  catalytically  break  down  the  components  of  the  
ECM.  A  gelatin  zymography  assay  was  employed  to  test  for  two  commonly  upregulated  
MMPs,  2  and  9.  Media  from  the  final  24  hour  treatment  on  the  spheroid  invasion  assay  
were  used  to  test  for  secreted  MMP-­‐‑2  and  MMP-­‐‑9.  Treatment  with  MCP-­‐‑1  did  not  
increase  the  latent  MMP-­‐‑2  or  latent  MMP-­‐‑9  secreted  by  MCF10A  cells,  nor  did  it  induce  
the  secretion  of  the  active  form  of  either  of  these  enzymes  (Figure  18).    
   In  summary,  MCP-­‐‑1  is  inducing  invasion  of  MCF10A  cells  in  3D  through  an  Erk  
signaling  pathway.  MCP-­‐‑1  treated  MCF10A  cells  are  not  secreting  MMP-­‐‑2  or  MMP-­‐‑9  to  
break  down  the  ECM.  Therefore,  further  investigation  is  required  to  elucidate  which  
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Figure  18:  MCP-­‐‑1  does  not  induce  MMP-­‐‑2  or  MMP-­‐‑9  
  
   Media  collected  after  the  last  24  hours  of  incubation  were  run  on  a  gelatin  
zymogram  gel.  Each  medium  contained  equal  amounts  of  latent  or  inactive  MMP-­‐‑2  and  
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3.5 Direct co-culture of MCF10A cells with ASCs in 3D induces 
MCF10A cell EMT and invasion 
 
   The  use  of  conditioned  media  or  recombinant  cytokine  treatment  does  not  allow  
direct  paracrine  signaling  that  might  occur  between  two  or  more  cells.  Additionally,  
both  paracrine  and  autocrine  feedback  loops  can  form  when  cells  are  grown  together.  
Therefore,  both  MCF10A  cells  and  ASCs  were  directly  co-­‐‑cultured  to  determine  whether  
direct  co-­‐‑culture  of  these  cells  induced  EMT  and  invasion.    
   The  presence  of  ASCs  induced  EMT  in  a  large  portion  of  the  MCF10A  cells  
(Figure  19).  MCF10A  cells  lost  expression  of  E-­‐‑cadherin  and  upregulated  Vimentin.  This  
induction  of  EMT  was  not  true  for  all  of  the  cells.  There  were  cells  that  maintained  their  
epithelial  phenotype  and  expressed  E-­‐‑cadherin.    
The  size  of  the  ASCs  made  it  possible  to  distinguish  between  the  mesenchymal  
MCF10A  cells  and  the  mesenchymal  ASCs.  Adipose  stromal  cells  stain  for  only  
Vimentin  similarly  to  the  mesenchymal  MCF10A  cells,  but  they  are  larger  and  
elongated.  
   The  MCF10A  cells  and  ASCs  were  both  separated  by  an  ECM  gel  at  the  
beginning  of  the  experiment.    Not  only  did  the  mesenchymal  MCF10A  cells  invade  
down  toward  the  ASCs,  but  the  ASCs  invaded  toward  the  MCF10A  cells.  Confocal  
microscopy  allowed  for  the  visualization  of  individual  planes  along  the  z-­‐‑axis  showing  
invading  cells.  Figure  19  shows  both  MCF10A  cells  and  ASCs  in  the  same  plane  despite  
being  separated  by  an  ECM  gel  at  the  beginning  of  the  experiment  (Figure  19).  
Additionally,  after  14  days  of  co-­‐‑culture,  the  ECM  was  noticeably  degraded  in  the  co-­‐‑
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cultured  cells  compared  to  the  single  cell  line  controls.  This  degradation  occurred  in  
both  independent  experiments,  and  it  made  the  immunofluorescence  processing  
difficult.  The  degradation  of  the  ECM  suggests  an  upregulation  of  MMPs  from  the  
invading  cells.  Further  investigation  will  be  needed  to  elucidate  the  mechanism  through  
which  the  MCF10A  cells  and  ASCs  invaded.  
   Taken  together,  direct  co-­‐‑culture  of  MCF10A  cells  with  ASCs  in  3D  ECM  induced  
EMT  in  MCF10A  cells.  Moreover,  direct  co-­‐‑culture  induced  invasion  in  both  the  
MCF10A  cells  and  ASCs.  Future  investigations  will  be  necessary  to  determine  whether  
direct  co-­‐‑culture  induced  additional  cytokine  or  growth  factor  secretion,  and  if  any  
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Figure  19:  ASCs  induce  MCF10A  EMT  and  invasion  in  3D  
  
   MCF10A  cells  grown  in  direct  co-­‐‑culture  with  ASCs  for  14  days  induced  loss  of  
E-­‐‑cadherin  staining  and  increase  in  Vimentin  staining.  Additionally,  MCF10A  cells  
invaded  down  through  the  Matrigel,  and  ASCs  invaded  up  through  the  Matrigel.  
Mesenchymal  MCF10A  cells  were  distinguishable  from  ASCs  by  size.  ASCs  were  
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4 Discussion 
4.1 Three-dimensional culturing is necessary for MCP-1 induced 
E-cadherin loss 
 
   Monocyte  chemoattractant  protein-­‐‑1  is  a  small  inflammatory  chemokine  that  
regulates  the  migration  and  infiltration  of  monocytes  and  macrophages  to  sites  of  injury  
or  inflammation  (49).  MCP-­‐‑1  binds  to  CCR2  and  can  signal  through  the  family  of  MAP  
kinases  (49,53,57-­‐‑58).  In  MCF10A  cells,  MCP-­‐‑1  rapidly  induced  the  phosphorylation  of  
Erk1/2.  Erk  signaling  is  associated  with  obesity,  involved  in  EMT,  migration,  and  
invasion  (61-­‐‑62,  65,  80-­‐‑83,  102).  Erk  signaling  is  also  associated  with  aggressive  TNBC  
(12).    The  activation  of  Erk  alone  by  MCP-­‐‑1,  however,  is  not  sufficient  to  induce  loss  of  
E-­‐‑cadherin  in  a  non-­‐‑transformed,  mammary  epithelial  cell  line  in  2D  culture.    
   MCF10A  acini  grown  in  ECM  lost  E-­‐‑cadherin  expression  when  treated  with  
MCP-­‐‑1.  The  addition  of  the  Erk  inhibitor  PD98059  inhibited  Erk  phosphorylation  and,  
consequently,  the  loss  of  E-­‐‑cadherin.  PD98059  inhibition  of  MCP-­‐‑1  induced  E-­‐‑cadherin  
loss  in  3D  suggests  that  the  activation  of  Erk  is  necessary  for  the  loss  of  E-­‐‑cadherin.      
There  are  examples  of  cytokine  treatments  in  literature  where  ECM  was  
necessary  to  observe  a  phenotype.  In  a  study  of  the  inflammatoray  cytokine  IL-­‐‑6,  it  was  
necessary  to  grow  the  luminal  breast  cancer  cells  in  ECM  prior  to  IL6  treatment  to  
induce  EMT  (27).  The  synergistic  signaling  contributed  by  the  ECM,  however,  has  yet  to  
be  elucidated  in  our  3D  model  of  MCP-­‐‑1  induced  E-­‐‑cadherin  loss  in  non-­‐‑transformed,  
mammary  epithelial  cells.    
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   The  extracellular  matrix  interacts  with  the  basal  pole  of  the  MCF10A  cells  
forming  acini.  The  interaction  between  ECM  and  cell  is  mediated  through  integrins.  
Integrins  are  involved  in  cellular  anchorage,  and  they  transmit  chemical  signals  into  the  
cell  providing  information  on  its  location,  local  environment,  adhesive  state,  and  
surrounding  matrix.  These  signals  from  integrins  determine  cellular  responses  such  as  
migration,  survival  and  differentiation.  Additionally,  integrins  provide  a  context  in  
which  the  cell  responds  to  other  external  inputs  transmitted  by  growth  factor  receptors  
or  G-­‐‑protein-­‐‑coupled  receptors  (68).    
   Integrins  signal  through  integrin-­‐‑linked  kinase  (ILK),  which  in  turn  can  
phosphorylate  Akt  at  S473  and  GSK-­‐‑3β  at  S9  (69,  70).  Akt  signaling  plays  a  prominent  
role  in  EMT  and  inhibition  of  GSK-­‐‑3β  can  lead  to  Snail  stabilization  and  EMT  (71-­‐‑74).    
Integrin  engagement  with  ECM  alone,  however,  does  not  induce  EMT  in  MCF10A  cells.  
MCF10A  cells  are  epithelial  when  they  form  acini  in  3D  culture  (63).  In  this  study,  
MCF10A  acini  stained  for  E-­‐‑cadherin  and  β-­‐‑catenin  localized  to  the  plasma  membrane,  
with  little  to  no  Vimentin  staining.  Additionally,  the  basal  staining  of  Integrin  α6  
indicated  proper  polarity  and  integrin  engagement.    
Further  investigation  into  the  contribution  of  ECM  and  integrin  signaling  need  to  
be  performed  in  order  to  elucidate  the  synergistic  signal  allowing  for  the  MCP-­‐‑1  induced  
E-­‐‑cadherin  loss.  Elucidating  the  role  of  integrin  signaling  can  be  accomplished  with  the  
use  of  pharmacological  inhibitors  against  ILK  to  determine  if  integrin  signaling  
contributes  to  MCP-­‐‑1  induced  E-­‐‑cadherin  loss.  Further  experiments  using  individual  
ECM  components,  collagen  IV  or  laminin,  can  be  performed  to  determine  which  ECM  
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protein  contributes  to  the  MCP-­‐‑1  induced  E-­‐‑cadherin  loss.  Elucidating  the  role  of  ECM  
in  MCP-­‐‑1  induced  E-­‐‑cadherin  loss  provides  a  potential  line  of  investigation  for  this  
project  moving  forward.      
4.2 MCP-1 induces migration in MCF10A cells 
   MCF10A  cells  express  CCR2,  which  is  the  receptor  for  MCP-­‐‑1.  Thus,  it  was  not  
surprising  when  MCP-­‐‑1  induced  migration  in  MCF10A  cells.  Regardless,  increased  
migration  is  still  an  important  phenotype  generated  by  MCP-­‐‑1.  It  shows  that  the  cells  are  
responding  to  MCP-­‐‑1  treatment.  Furthermore,  inhibition  of  migration  with  PD98059  
indicates  that  migration  is  controlled  through  an  Erk  signaling  pathway.  While  this  may  
be  true,  cells  aren’t  able  to  migrate  in  tissue  as  they  would  on  plastic.  Thus,  the  more  
biologically  pertinent  question  was  whether  they  could  invade  a  biological  matrix.    
4.3 MCP-1 induces invasion in MCF10A cells 
   In  a  spheroid  gel  invasion  assay,  MCF10A  spheroids  treated  with  MCP-­‐‑1  lost  
their  distinct  borders,  and  cells  invaded  the  surrounding  matrix.  In  some  instances,  
MCF10A  cells  invaded  the  matrix  and  reached  the  plastic  below.  This  invasion  was  not  
observed  in  the  untreated  controls.  Additionally,  PD98059  inhibited  MCP-­‐‑1  from  
inducing  invasion  of  cells  into  the  surrounding  matrix.  These  data  provide  evidence  of  
MCP-­‐‑1  induced  invasion  in  a  non-­‐‑transformed,  mammary  epithelial  cell  line.  Invasion  is  
more  biologically  relevant  because  in  vivo  cells  have  to  pass  through  basement  
membranes  to  escape  and  metastasize.    The  primary  advantage  of  the  spheroid  gel  
invasion  assay  is  that  it  mimics  in  vivo  invasion  where  cell  clusters  with  well-­‐‑established  
cell-­‐‑cell  interactions  break  through  basement  membranes.  In  a  modified  Boyden  
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invasion  assay,  however,  individual  cells  pass  through  ECM  and  a  membrane,  which  
does  not  mimic  in  vivo  invasion  (17,  66).    
Gelatin  zymography  tested  for  the  presence  of  MMPs  secreted  into  the  media  to  
elucidate  the  mechanism  by  which  MCF10A  cells  were  invading.  Although  gelatin  
zymography  can  be  used  to  detect  several  MMPs,  it  is  best  for  the  assessment  of  the  
gelatinases:  MMP-­‐‑2  and  MMP-­‐‑9  (75-­‐‑76).  All  conditions  in  the  3D  MCF10A  spheroid  gel  
invasion  assay  secreted  pro-­‐‑MMP-­‐‑2  and  pro-­‐‑MMP-­‐‑9  into  the  media.  There  were  no  
active  forms  of  either  MMP-­‐‑2  or  MMP-­‐‑9  secreted  into  the  media.  Thus,  neither  MMP-­‐‑2  
nor  MMP-­‐‑9  is  contributing  to  the  invasion  in  the  MCP-­‐‑1  treated  speroids.  There  are,  
however,  other  MMPs  that  might  be  secreted  upon  treatment  with  MCP-­‐‑1.    
Collagen  gel  zymography  would  be  more  informative  for  collagenases,  such  as  
MMP-­‐‑1,  8,  and  13  (76).  Collagen  zymographic  gels,  however,  are  not  available  
commercially  and  can  be  very  difficult  to  properly  polymerize.  A  Human  MMP  
Antibody  Array  from  RayBiotech  is  an  affective  alternative  because  it  will  show  all  of  
the  MMPs  secreted  into  the  media.  The  MCP-­‐‑1  treated  spheroid  media  could  then  be  
compared  to  all  other  conditions  for  changes  in  MMP  secretion.  This  line  of  investigation  
will  have  to  be  undertaken  by  a  future  investigator  within  the  lab.    
4.4 Direct co-culture of MCF10A and ASC cells 
   Directly  co-­‐‑culturing  MCF10A  cells  with  ASCs  provides  paracrine  signaling  
between  the  two  cell  lines  that  conditioned  media  alone  can  not.  When  both  cells  are  
grown  together,  it  is  possible  that  there  are  feedback  loops  or  additional  signaling  
molecules  involved  that  have  yet  to  be  observed.  The  long-­‐‑term  culture  of  MCF10A  cells  
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in  ASC-­‐‑conditioned  media  caused  the  secretion  of  IL8  and  MCP-­‐‑1  back  into  the  media.    
Consequently,  there  are  additional  cytokines  or  growth  factors  that  may  be  secreted  
when  these  cells  are  grown  together.  
   Though  this  line  of  investigation  requires  further  exploration,  it  is  known  that  by  
co-­‐‑culturing  both  of  these  cell  lines  together  in  3D  produced  an  EMT  where  E-­‐‑cadherin  
was  lost  and  Vimentin  was  upregulated.  Additionally,  the  invading  cells  broke  down  
the  ECM  to  where  it  was  nearly  impossible  to  process  the  sample  for  
immunofluorescence.  Thus,  a  model  system  has  to  be  developed  where  it  is  possible  to  
study  the  paracrine  signaling  of  both  cell  lines  and  the  resulting  EMT  induced  in  the  
MCF10A  cells.    
   This  very  model  system  is  currently  being  developed  in  the  Seewaldt  lab.  
Different  co-­‐‑culturing  models  are  being  tested  to  best  answer  different  questions.  Once  
these  models  are  developed,  future  investigators  in  the  lab  will  be  able  to  ask  questions  
regarding  adipose  signaling  using  several  different  ASCs  to  determine  if  there  are  
differences  between  ASCs  derived  from  healthy  or  diseased  breasts,  obese  or  non-­‐‑obese  
patients,  and  race.    
4.5 The role of MCP-1 and obesity in breast cancer 
   It  is  well  established  that  obesity  increases  the  risk  of  several  cancers  through  its  
role  as  a  chronic  inflammatory  condition  (14-­‐‑16).  Several  groups  have  shown  that  there  
are  elevated  levels  of  IL6,  IL8,  IL1β,  TNFα,  VEGF,  Leptin  and  MCP-­‐‑1  in  obese  adipose  
and  that  circulate  through  the  body  (13-­‐‑15,  35-­‐‑37,  50-­‐‑51).  The  constant  assault  by  these  
inflammatory  cytokines,  growth  factors,  and  hormones  have  been  shown  to  contribute  
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to  the  development  of  cancer  in  several  organs.  Obesity  appears  to  affect  people  
differently.  The  Carolina  Breast  Cancer  study  showed  that  obesity  in  premenopausal  
women  put  them  at  higher  risk  for  TNBC,  while  postmenopausal  women  were  at  
increased  risk  for  ER+  cancers  (7-­‐‑9).  
   Elevated  levels  of  MCP-­‐‑1,  as  a  result  of  increased  adiposity,  can  affect  the  breast  
two  fold.  Firstly,  there  are  the  direct  effects  of  MCP-­‐‑1  on  the  epithelial  cells  of  the  breast.  
This  is  what  was  being  been  studied  in  this  investigation.  There  are  also  indirect  effects  
that  MCP-­‐‑1  may  have  on  the  formation  of  a  carcinoma  of  the  breast.  MCP-­‐‑1  is  a  
chemokine  that  regulates  the  migration  and  infiltration  of  monocytes  and  macrophages  
(49).  Increased  adiposity  in  the  breast,  and  thus,  MCP-­‐‑1,  can  cause  an  increase  in  the  
number  of  monocytes  and  macrophages  present  in  the  breast.  This  increase  in  
monocytes  and  macrophages  could  further  exacerbate  the  inflammation  in  the  breast.  
Furthermore,  MCP-­‐‑1  has  been  shown  to  recruit  bone  marrow  derived  mesenchymal  
stem  cells  to  forming  tumors  (77).  Lastly,  MCP-­‐‑1  can  induce  kidney  and  peritoneal  EMT  
and  fibrosis  (78-­‐‑79,  90-­‐‑94).  Taken  together,  MCP-­‐‑1  contributes  to  carcinogenesis,  but  
further  investigation  will  be  required  to  elucidate  the  full  extent  to  which  MCP-­‐‑1  is  
involved  in  mammary  carcinogenesis.    
This  investigation  has  provided  data  that  suggest  that  MCP-­‐‑1,  an  adipose  
derived  chemokine,  can  induce  the  loss  of  E-­‐‑cadherin  and  invasion  in  a  non-­‐‑
transformed,  mammary  epithelial  cell  line.  The  loss  of  E-­‐‑cadherin  is  a  key  step  in  EMT,  
and  invasion  is  a  necessary  step  in  the  metastatic  process  (20).  Both  EMT  and  distal  
metastasis  associate  with  aggressive  triple  negative  breast  cancers  (11-­‐‑12,  24-­‐‑25,  61-­‐‑62,  
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85,  98).  Although  not  an  exhaustive  investigation,  this  study  provides  a  foundation  from  
which  future  investigators  can  begin  to  ask  questions  regarding  MCP-­‐‑1  and  other  
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